DermAvance Acquires Hyalogy® –
Novel Nanotechnology for Skincare
Berywn, PA, August 15, 2006 – DermAvance Pharmaceuticals, a privately held pharmaceutical company specializing in advanced technology applications for skin health and cosmetic dermatology, today announced the acquisition of the North American rights for the Hyalogy™ Total Skin Care Line from Forlle’d in Japan.
Hyalogy™ P-effect represents a novel breakthrough formulation technology, using a proprietary nanotechnology process, to create the first product for the cosmeceutical market that allows topically applied hyaluronic acid to penetrate the skin’s epidermal barrier. The Hyalogy™ Total Skin Care Line is designed to provide deep hydration into the skin more effectively and for a prolonged period of time over current formulations of traditional skin moisturizers.
The amount of moisture in skin, a source of youth and beauty, decreases with age. Hyaluronic acid, a naturally occurring substance produced by the body, is what gives skin its volume and fullness. Adults have only 1/20th of the amount of hyaluronic acid as a baby. Until now, hyaluronic acid had to be injected into the dermis because earlier formulations were not able to penetrate the skin topically. With extensive research efforts, using advanced infiltration nanotechnology, an ultra low molecular weight hyaluronic acid with superior ability to penetrate through to the deep layers of the skin has been created. Hyalogy™ P-effect conveys the extraordinary function of hyaluronic acid and delivers moisture deep beneath the skin surface without the use of needles. “The unique advantage of Hyalogy™ P-effect is its ability to penetrate deep beneath the skin’s epidermal barrier”, said W. Philip Werschler, MD/FAAD, board certified dermatologist and Assistant Clinical Professor at the University of Washington School of Medicine.
“The introduction of cosmeceutical nanotechnology will not only significantly effect cosmeceutical formulations but may very well revolutionize drug delivery systems in a number of key areas” commented Keith Greathouse, President and CEO of DermAvance. “We are very excited about our collaboration with Forlle’d, who is at the forefront of nanotechnology development in cosmetic dermatology and innovative cosmeceutical formulations. We expect to launch the Hyalogy™ Total Skin Care Line early in the 4th Quarter, 2006.”
About DermAvance Pharmaceuticals, Inc.
DermAvance Pharmaceuticals, Inc. is a privately held dermatology pharmaceutical company focused on commercializing unique, and innovative anti-aging products to enhance the health and appearance of skin. The company was founded to meet the rapidly growing demand for facial skin rejuvenation products. DermAvance expects to launch several unique product lines in the 4th Quarter of 2006, including Vivelif® (acetyl hexapeptide-3), an innovative topical peptide preparation designed to reduce the visible signs of aging by targeting biochemical mechanisms of wrinkle formation similar to the activity of neurotoxins. DermAvance markets and sells products directly to dermatologists and aesthetic physicians for in-office dispensing.
For additional information contact:
Kathleen Sugg (610) 727-3959
Vice President of Marketing
Keith Greathouse (610) 727-4066
President & CEO